Huminsulin Basal (Insulin Human)

Huminsulin Basal is indicated for the long‑term control of hyperglycaemia in adults with diabetes mellitus.

• As basal insulin therapy for type 1 diabetes to maintain steady glucose levels.
• As part of a basal‑bolus regimen in type 2 diabetes when oral agents are insufficient.
• In combination with rapid‑acting insulin analogues for intensive insulin therapy.
• For patients requiring once‑daily or twice‑daily dosing to simplify management.
• To reduce the risk of chronic complications associated with poorly controlled blood sugar.

• Insulin human in Huminsulin Basal binds to insulin receptors on the surface of muscle, adipose and hepatic cells. This interaction triggers autophosphorylation of the receptor’s β‑subunit, activating the intracellular PI3‑kinase/Akt signaling cascade. The cascade promotes translocation of GLUT‑4 transporters to the cell membrane, enhancing glucose uptake, and suppresses hepatic gluconeogenesis, thereby lowering circulating blood glucose concentrations and improves overall metabolic homeostasis.

Like other basal insulins, Huminsulin Basal may be associated with a range of adverse reactions, most of which are mild and transient.

Common

• Injection site pain, redness or swelling.
• Mild hypoglycaemia, especially if meals are missed or delayed.
• Weight gain due to increased caloric storage.
• Lipodystrophy at the injection site, presenting as lipoatrophy or lipohypertrophy.

Serious

• Severe hypoglycaemia with neuroglycopenic symptoms such as confusion or seizures.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Edema or heart failure exacerbation in susceptible individuals.
• Persistent hyperglycaemia indicating possible insulin resistance or dosing issues.

When prescribing Huminsulin Basal, clinicians should evaluate patient history and monitor for conditions that could alter insulin requirements or increase risk of adverse events.

• Assess renal and hepatic function, as impairment may affect insulin clearance.
• Review history of hypoglycaemia unawareness before initiating therapy.
• Use caution in patients with cardiovascular disease or heart failure.
• Adjust dose during periods of illness, surgery, or significant changes in physical activity.
• Educate patients on proper injection technique to minimise lipodystrophy.
• Monitor pregnancy status; insulin requirements often change during gestation.
• Avoid use in individuals with known hypersensitivity to human insulin.

Huminsulin Basal can interact with other medications that affect glucose metabolism or insulin action, requiring dose adjustments or monitoring.

Avoid

• Concurrent use of other rapid‑acting insulins without appropriate dose reduction.
• High‑dose beta‑blockers that may mask hypoglycaemia symptoms.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, which increase hypoglycaemia risk.
• Corticosteroids, which can raise blood glucose and may necessitate higher insulin doses.
• Thiazide diuretics, which may impair glucose tolerance.
• ACE inhibitors or ARBs, which can potentiate insulin’s glucose‑lowering effect.
• Alcohol consumption, especially in excess, as it can cause unpredictable glucose fluctuations.